| 【Company Research】CSPC Pharmaceutical (1093 HK) – Encouraging preliminary clinical results of mRNA COVID-19 vaccine candidate |
| 【Fixed Income Research】JIAYUA: The exchange, consent and RSA |
| 【Company Research】Ping An (2318 HK) – Channel reform is close to the finish line |
| 【Company Research】Jiumaojiu (9922 HK) – Re-opening, margins & Song are key drivers |
| 【Company Research】Xtep (1368 HK) – Inventory not a worry and guidance maintained |
| 【Company Research】Anta Sports (2020 HK) – Anta/ FILA to turn around & Amer to break even |
| 【Company Research】GDS (GDS US) – Lacks visibility in recovery timeline |
| 【Company Research】GDS (9698 HK) – Lacks visibility in recovery timeline |
| 【Company Research】Kuaishou (1024 HK) – Another upbeat quarter; 2H22E outlook on track |
| 【Company Research】Glodon (002410 CH) – Penetrating into basic infrastructure segment |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
